Early-onset dominantly inherited forms of Alzheimer's disease (AD) are rare, but studies of such cases have revealed important information about the disease mechanisms. Importantly, mutations in amyloid precursor protein (APP), presenilin 1 (PSEN1) and PSEN2, alter the APP processing and lead to an increased amyloid b-peptide (Ab) 42/40 ratio. This, together with other studies on pathogenic mechanisms, show that Ab42 is a major player in the etiology of AD. Here, we present a clinical and neuropathological description of a Swedish family with an I143T mutation in the PSEN1 gene, which gives rise to a severe form of AD. We also performed an extensive investigation on the concentration and distribution of Ab species of different lengths in six brain regions from two mutation carriers. Our study showed that Ab42 and a longer peptide, Ab43, were present both in plaque cores and in total amyloid preparations, and were each clearly more frequent than Ab40 in all examined regions, as shown by both mass spectrometry and immunohistochemistry.
INTRODUCTION
Alzheimer's disease (AD) is a neurodegenerative disorder and a major cause of dementia, characterized by amyloid b-peptide (Ab) deposits and neurofibrillary tangles in brain. [1] [2] [3] Ab is typically 40 or 42 amino acids long and is produced by the sequential cleavages of the amyloid precursor protein (APP) by b-secretase and g-secretase. 4 The presenilins (1 and 2) are important components of the g-secretase complex, and harbor its active site and thereby influence its proteolytic effect. Ab40 is produced at higher levels, but as Ab42 is more hydrophobic and has a stronger tendency to polymerize into neurotoxic species, it seems to be of particular importance in AD pathogenesis. [5] [6] [7] This is supported by studies on mutations in APP, presenilin 1 (PSEN1) and PSEN2, which show an increased Ab42/40 ratio. 8 Five mutations have previously been described in families from Sweden: two mutations in APP (the APP Swedish 9 and the APP Arctic mutations 10 ) and three in PSEN1 (M146V, H163Y, 11 and R269H 12 ). In the present study, we describe the clinical characteristics of a three-generational Swedish family found to have the I143T PSEN1 mutation, which causes a rapidly progressing type of early-onset AD (EOAD). The g-secretase complex with the I143T mutation in PSEN1 has been suggested to produce Ab peptides of different lengths. 13 We recently reported that a longer variant, Ab43, is present in plaque cores and in total amyloid preparations obtained from sporadic and familial AD brains, and was indeed found more frequently than Ab40. 14 A quantitative approach was used to study Ab40, Ab42, and Ab43 in two mutation carriers diagnosed with a severe and aggressive form of EOAD by examining samples taken from six brain regions, including the frontal, parietal, temporal, and occipital cortex, as well as anterior hippocampus and cerebellum. High-performance liquid chromatography (HPLC) coupled with an electrospray ionization ion-trap mass spectrometer (MS) was used. In parallel, we performed immunohistochemistry on consecutive sections using antibodies directed against Ab40, Ab42, and Ab43. In addition, secreted and cellular Ab was analyzed in cultured fibroblasts from mutation carriers and controls using a highly sensitive ELISA.
MATERIALS AND METHODS
The study was approved by the Regional Ethics Committee in Stockholm and informed consent was obtained from the participants, or from a proxy.
Sample preparation for neuropathological examination and immunohistochemistry
The left halves of the brains were frozen after death and the right halves were fixed in 4% formaldehyde. Samples from the different regions, such as hippocampus, amygdala, basal ganglia, thalamus, mesencephalon, brainstem, and cerebellum, were collected from the fixed brains. In addition, one gross section of the cerebral hemispheres was collected from each patient.
Staining was performed on 5-mm-thick formaldehyde-fixed paraffinembedded sections. Sections were routinely stained with hematoxylin and eosin, Luxol fast blue, Bielschowsky, and AT8 antibody. Some sections were also Congo stained to detect amyloid. Immunohistochemistry was performed on
Preparation of SDS-insoluble brain homogenates
A previously described protocol for SDS preparations was followed. 14 In brief, the samples were homogenized as described above. The homogenate was centrifuged at 50 000 g for 1 h. The resulting pellet was re-homogenized in TBS with 1% SDS and centrifuged at 50 000 g for 1 h. This procedure was repeated three times. The final pellet was washed five times in TBS and stored at À201C.
Dissolution and cleavage of brain samples
The purified plaque cores as well as pellets from the SDS preparations were dissolved in 80% FA and 4 mg of cyanogen bromide (CNBr) in a shaker at 600 r.p.m. overnight at 371C. CNBr cleaves the methionine at the C-terminal end (generating Ab36-x fragments). Samples were prepared for LC-MS/MS analysis by concentrating and desalting the samples using C 18 ZipTips (Millipore Corporation) according to the manufacturer's instructions, and then dried in a vacuum centrifuge (Maxi dry lyo, Heto, Alleröd, Denmark) and dissolved in 40 ml of 0.1% FA. Finally, 0.5 ml of the plaque core samples and the SDS preparations was injected into the LC-MS/MS analysis system.
Quantification
The synthetic Ab peptides Ab36-40, Ab36-42, and Ab36-43 (Bachem, Basel, Switzerland) were used as standards for quantifications as described previously. 14 The peptides were dissolved in 80% FA and diluted in 0.1% FA. Standard curves were plotted by mixing Ab36-40, Ab36-42, and Ab36-43 at a ratio of 20:20:1 and by injecting 1 ml of 500, 200, 50, and 20 fmol of Ab36-40 and Ab36-42, and 25, 10, 2.5, and 1 fmol of Ab36-43 in the same solution. The monoisotopic masses for the Ab fragments were plotted as extracted ion chromatograms. The peak areas were used in the equations from the standard curves to calculate the concentrations of Ab in the tissue samples, which were expressed as nmol of Ab per g of wet brain tissue. The total CNBr cleavage yield as well as the yield from the plaque core preparation procedure as established previously were taken into account in the calculations. 14 
HPLC-MS/MS
The samples were injected into a high-capacity enrichment column chip with a 160-nl enrichment column and a 75 mmÂ150 mm analytical column packed with Zorbax C18-SB 5-mm material (Agilent Technologies, Santa Clara, CA, USA). As described before, 14 peptides were eluted using a water/acetonitrile (ACN) gradient supplemented with 0.2% FA, from 2 to 14% ACN in 20 min and from 14 to 95% ACN in 20 min. The flow rate was 0.4 ml/min, delivered by an Agilent 1200 nano pump (Agilent Technologies). The column chip was coupled to an Agilent ion trap mass spectrometer (6330 Ion Trap LC/MS, Agilent Technologies). Mass spectra were recorded from the mass to charge ratio (m/z 420 to m/z 750). The identity was confirmed using MS/MS data.
Fibroblast culture
Skin biopsy samples were taken and fibroblast cells were prepared as described. 15 Fibroblast cell cultures from case III:1 were compared with selected cases, including an individual with the APP KM670/671NL Swedish mutation (APPSwe; onset age 58, biopsy at 66 years) and three unrelated, gendermatched and cell-passage-matched controls (mean age at biopsy: 43.7 years; range 26-53 years). Measurements of secreted and cellular Ab40 and Ab42 using ELISA provided the basis for comparison. The fibroblast cells were cultured in duplicate in 5 ml of minimum essential medium with Earl's salt (MEM), supplemented with 7.5% heat-inactivated fetal bovine serum, 10 mM HEPES, 1.2% L-glutamine, and 1.2% pencillin-streptomycin (all reagents from GIBCO, Invitrogen, Carlsbad, CA, USA). In parallel, fibroblast samples from the I143T, the APPSwe, and two of the controls were also cultured in the presence of the g-secretase inhibitor L-685.485 (Bachem, Bubendorf, Switzerland) at a final concentration of 10 mM till the collection of the cell medium. When the cells reached B100% confluency, the cell medium was replaced with serum-free MEM, supplemented with 10 mM HEPES and 1.2% L-glutamine, and incubated for 24 h, after which Complete protease inhibitor cocktail (Roche Applied Science) was added to the cell culture. The medium was removed, aliquoted in Genuine Axygen Quality 1.5-ml microtubes (Axygen, Union City, CA, USA), and stored at À801C for future analysis. The remaining cells were treated with 1 ml of 1Â RIPA buffer (150 mM NaCl, 1% NP-40, 0.5% deoxycholic acid, 0.1% SDS, 50 mM Tris, pH 8) containing Complete protease inhibitor cocktail (Roche Applied Science), and harvested by scraping on ice. The cells were collected in Genuine Axygen Quality 1.5-ml microtubes (Axygen) and centrifuged at 25 000 g for 1 h at 41C. The cell pellet and the supernatant (sup1) were stored at À801C for future analysis.
ELISA
Ab40 and Ab42 secreted into the cell medium, and cellular (RIPA-soluble) Ab40 and Ab42 were measured in triplicate using ELISA (Human/Rat b-Amyloid (40) ELISA Kit Wako II and Human/Rat b-Amyloid (42) ELISA Kit Wako, High-Sensitive from WakoPure Chemical Industries, Osaka, Japan). As the levels of secreted Ab40 were below the detection limit for the Wako kit, secreted Ab1-40 in the medium was instead analyzed using the Human Amyloid-b (1-40) (FL) Assay Kit-IBL (IBL International GmbH, Hamburg, Germany). FLUOStar Galaxy (Thermo Scientific, Fremont, CA, USA) was used to measure the fluorescence. Before the cell medium samples and standards were loaded on the ELISA plate, 5Â RIPA buffer was added to a final concentration of 1Â RIPA buffer. In all, 200 ml of 1Â RIPA buffer was added to the cell pellet and sonicated for 10 min, followed by centrifugation at 25 000 g for 1 h at 41C, generating supernatant 2 (sup 2). Sup 1 and 2 were pooled; the pooled samples thus contained the 1Â RIPA-soluble cellular Ab, before loading onto the ELISA plate. The ELISA procedure was according to the manufacturer's protocol, except that TMB was exchanged with a 1Â PBS solution containing 50 mM Amplex UltraRed reagent (Invitrogen, Eugene, OR, USA), and 2.2 mM H 2 O 2 was added to each well before measuring the fluorescence, which was done using a 544 nm excitation filter and 590 nm emission filter, Ab variants in brains from PSEN1 mutation carriers L Keller et al thus effectively increasing the sensitivity. Concentrations of Ab40 and Ab42 secreted into the cell medium and RIPA-soluble cellular samples (sup 1 and sup 2) were calculated from standard curves. The mean Ab concentration was then normalized against the total cellular protein concentration measured using the Pierce BCA Protein Assay Kit (Thermo Scientific, Rockford, IL, USA) according to the manufacturer's protocol.
RESULTS

Clinical characteristics
In a Swedish family, five family members across three generations were affected with pre-senile dementia (Figure 1 ). The age of onset was 35.6 ± 2.1 years (mean ± SD) and age at the first AD-related medical visit was 36.2±1.9 years. The mean age of death was 42.4±1.3 years and the duration of the disease from onset to death was 6.8±2.4 years. Initial symptoms were typical for AD and included memory impairment, visuospatial difficulties, disorientation, dyspraxia, and dysphasia. However, these symptoms were not always reported until the patient was admitted to hospital in acute condition, owing to falls or epileptic seizures. Additional early findings were coordination difficulties associated with gradually increasing myoclonic jerks, multiple falls, and, in some cases, epileptic seizures. These neurological symptoms made differential diagnosis difficult, specifically between AD and Huntington's disease. The latter diagnosis was excluded, however, by genetic testing. In the later stages of the disease, psychiatric symptoms such as paranoid delusions, hallucinations, and aggressiveness appeared and, in the first generation, Pick's disease was suspected owing to the observed personality changes. Within the youngest generation, cholinesterase inhibitor treatment was tried but did not seem to slow down the rapid progression of the disease. Anti-epileptic treatment seemed to reduce myoclonic jerks. For an overview of the clinical presentation, see Supplementary Table 1 , and for a detailed description of the symptoms, clinical course, and treatment of the family members, see Supplementary Text 1.
Neuropathological examination
Brains from three mutation carriers (cases II:2, III:2, and III:1) were subjected to autopsy. A definite diagnosis of AD was established for cases III:1 and III:2 according to the CERAD criteria, and Braak stage VI. Case II:2 was diagnosed as atypical AD in 1985, owing to the prominence of pathology associated with the corpus striatum, which are not typically seen in AD cases. However, a recent re-examination revealed severe AD pathology. In summary, all brains were severely affected by Alzheimer's pathology and atrophy. Macroscopically, the frontal lobes were especially affected by the thinning of gyri and the reduced cortical thickness, whereas microscopically a large number of plaques were observed, often without a distinct plaque core. Tau pathology, including numerous ghost tangles, was widespread and severe in the hippocampal areas, entorhinal cortex, and amygdala. Superficial spongiform changes and gliosis were present. Interestingly, some neurons in the granular cell layer of the dentate gyrus were immunoreactive for the AT8 antibody, which recognizes the phosphorylated tau. The cerebellum, which often is relatively spared in AD, was clearly affected by amyloid in cases III:1 and III:2. For a detailed neuropathological description, see Supplementary Text 2.
Molecular genetics -identification of the pathogenic mutation
The family showed a clear pattern of dominantly inherited neurodegenerative disease; the neuropathological investigation of case III:2 prompted us to suspect early-onset AD and to screen for a mutation in PSEN1. A heterozygous point mutation was found in the second base in codon 143 of exon 5 in PSEN1, which results in an amino-acid exchange of isoleucine to threonine in the second transmembrane region of the PSEN1 protein. Restriction enzyme cleavage of the exon 5 PCR fragment using Tsp45 I resulted in two extra and shorter bands in addition to the 300-bp-long wild-type fragment, thereby confirming the presence of the I143T mutation (data not shown). The mutation was detected in genomic DNA from each of the three cases: II:2, III:1, and III:2 ( Figure 1) . Moreover, one variation was found in intron 8 (rs165932), which has previously been studied (http://www.alzgene.org/meta.asp?geneID¼84). This variation is a common polymorphism and should not be considered as informative. No other genetic variation was found. Cases II:2, III:1, and III:2 were all APOE e3e3 homozygotes.
Analysis of Ab C-terminal fragments in plaque cores and SDS-insoluble material By using LC-MS, we quantified the amounts of the different Ab C-terminal variants in plaque cores and the total amyloid SDSinsoluble material from frontal, parietal, temporal, and occipital cortex samples, as well as from the anterior hippocampus and cerebellum of two PSEN1 I143T mutation carriers (cases III:1 and III:2; Figure 1 ). Standard curves were plotted and used for calculations of the Ab concentrations (Supplementary Figures S1A, S1B , and S1C, Supplementary Data). In plaque cores, Abx-42 was readily detected in all regions from both patients. The lowest concentration was found in the cerebellum and the highest in the occipital cortex. Abx-43 was found in all regions from both cases, except for the cerebellum, where it was not detected. In both cases, the highest concentration was found in the occipital cortex. Interestingly, Abx-40 was not detected in any of the regions obtained from the two cases (Figure 2a) . We also analyzed total Ab in SDS-insoluble material from brain homogenates. Abx-42 was readily detected in all regions in both patients. The lowest concentration of Abx-42 was found in the cerebellum, whereas the highest concentration was found in the occipital cortex. Abx-43 was readily detected in all regions from both cases (Figure 2b) . Interestingly, Abx-40 was detected only in the occipital cortex and the cerebellum of case III:2.
Immunohistochemistry
Antibodies specific for the C-terminus of Abx-40, Abx-42, or Abx-43 were used to stain consecutive sections taken from the six regions of the two cases. The staining of Abx-40 was low in the occipital cortex in both cases, and was only detected in vessels (Figure 3a and d) , whereas Abx-42 staining was intense in both cases, with numerous immunoreactive plaques (Figure 3b and e) . Many immunoreactive plaques were also evident by the Abx-43 antibody (Figure 3c and f) . Although the methodology used does not allow for quantification and co-localization of the immunoreactivity, visual inspection in the microscope revealed that Abx-42 and Abx-43 immunoreactivity was detected in both plaques and vessels, whereas Abx-40 showed immunoreactivity mainly in vessels (Figure 3g, h and i) . In the cerebellum, Abx-40 staining was clearly visible only in a few vessels, most prominently in case III:2 (Figure 3j and m) . Abx-42 staining was observed in vessels in both cases (Figure 3k and n) . Abx-43 staining was positive in vessels and the pattern was similar to the Abx-42 staining in both cases (Figure 3l and o) . Moreover, extracellular Abx-42 and Abx-43 staining was also observed in an uneven and diffuse pattern in the molecular layer.
The immune staining of the frontal, temporal, and parietal cortex, as well as hippocampus, showed little or no Abx-40 immunoreactivity, 
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and when present, it was only observed in vessels, a pattern seen also in the occipital cortex and the cerebellum. Abx-42 was positive in both plaques and vessels, and Abx-43 seemed to have a similar staining pattern (data not shown) in these four regions.
Ab production in cultured fibroblasts from mutation carriers and controls As a complement, a sensitive ELISA was implemented to measure Ab production in cultured fibroblasts. Results showed that secreted Ab40 levels were low in both the PSEN1 I143T mutation carrier (case III:1) and the healthy controls (o5 pmol per g total protein), although the level was five times higher in the APPSwe carrier (B25 pmol per g total protein). Secreted Ab42 levels were also low (r1 pmol per g total protein) and equal in all samples, except the APPSwe mutation carrier, in which the concentration was about three times higher (2.8 pmol per g total protein). In the presence of the g-secretase inhibitor, L-685.485, no Ab was detected (data not shown). The ratio of secreted Ab42/40 was highest in the PSEN1 I143T carrier (0.5; Figure 4a ). The cellular Ab40 concentration was equivalent in all samples (40-55 pmol per g total protein) and significantly higher when compared with secreted Ab40 (about two times higher in the APPSwe carrier, and up to 50 times higher in the PSEN1 I143T mutation carrier and the healthy controls). The cellular Ab42 concentration was higher across all samples (B8 pmol per g total protein) than the secreted Ab42 concentration (0.5-2.8 pmol per g total protein). Therefore, the cellular ratio of Ab42/40 was similar (0.14-0.16) across all samples (Figure 4b) . No significant inhibition of Ab was detected in the presence of the g-secretase inhibitor, L-685.485 (data not shown).
DISCUSSION
In the present study, we identified a PSEN1 I143T mutation in three cases diagnosed with neurodegenerative disease from two generations in a Swedish family. This mutation has previously been reported to cause EOAD both in single unrelated cases, related cases and in two families in which segregation was proven, but clinical, neuropathological, and biochemical details have been lacking. [16] [17] [18] [19] [20] [21] [22] [23] The form of EOAD recurring in this family is severe and its mean onset age is reported to be 34 years, whereas the mean age of death is 41.2 years (http://www.molgen.ua.ac.be/ADMutations). Our clinical investigation revealed an aggressive form of AD with rapid progression and extensive myoclonia. Among the clinical characteristics shown in this Swedish family were insidious impairment of memory, visuospatial disorientation, dyspraxia, and dysphasia, as well as coordination problems, including myoclonic jerks and multiple falls, and in some cases epileptic seizures. The clinical characteristics of the Belgian family with the same mutation, described as early as in 1940 as 'une observation hérédo-familiale de démence avec épilepsie et clonismes' , 16, 18, 24 were similar to the characteristics of the Swedish family in terms of age at onset, increased aggressiveness, rapid loss of memory, myoclonus, and seizures.
We performed quantitative and qualitative biochemical studies of Ab pathology on six brain regions sampled from two cousins known to have the I143T mutation. Interestingly, we found that a long Ab species, ending with Thr43, was present in plaque cores in all regions except in cerebellum. In all the analyzed regions, Abx-43 was found more frequently than Abx-40, as shown by both mass spectrometry analysis and immunohistochemistry. The highest concentrations of both Abx-42 and Abx-43 were found in the occipital cortex from both mutation carriers. This supports the notion that the occipital cortex is a plaque core-rich region. 25 Even though immunostaining in both cases showed that the cerebellum was affected by Ab pathology, the lowest plaque core concentration of Abx-42 was found in preparations from this area, and moreover, Abx-43 was not detected by mass spectrometry. The concentrations of Abx-42 were similar in the frontal cortex and anterior hippocampus. The levels were higher in both the parietal and temporal cortex than in either the frontal cortex or anterior hippocampus. There were no significant differences in the concentration of Abx-43 between these regions. In accordance with earlier studies, 6 we conclude that Ab42 is the predominant species in amyloid plaque cores in the AD brain. Notably, there were no detectable levels of Abx-40 in plaque cores, which is in line with previous results. 6 As Ab is deposited not only in plaque cores in the AD brain, but also in the walls of the cerebral vessels as diffuse deposits, we studied the total Ab from the two cases by analyzing Ab peptides in the material from SDS-insoluble preparations. Abx-42 and Abx-43 were readily detected in all regions. The concentrations were highest in the occipital cortex and lowest in the cerebellum. Interestingly, there were no detectable levels of Abx-40 in the SDS-insoluble preparations except in the cerebellum and the occipital cortex of case III:2. The levels of Abx-40 in these regions most likely stem from amyloid in cerebral vessels associated with cerebral amyloid angiopathy, which is reported to be composed mainly of Abx-40. 6, 26 As Abx-40 has a lower aggregation propensity compared with the longer Ab species, differences in Abx-40 levels between the cases might be explained by the longer duration of the disease in case III:2, as compared with case III:1. Mass spectrometry data are also supported by the immunohistochemical analysis of the six regions, which showed that Abx-40 was localized mainly to the cerebral vessels, whereas Abx-42 and Abx-43 were more prominent in plaques.
Using ELISA, we measured the concentrations of cellular and secreted Ab40 and Ab42 in cultured fibroblasts sampled from a PSEN1 I143T mutation carrier, an APPSwe mutation carrier, and three healthy controls. The APPSwe mutation carrier differed notably, with higher concentrations of secreted Ab40 and Ab42 compared with all other samples. Cellular Ab40 and Ab42 concentrations did not differ significantly between the samples and the levels of Ab42 were lower in comparison with Ab40. The highest ratio of Ab42/40 was observed in the secreted fraction from the I143T mutation carrier, in line with previous studies on PSEN1 mutations. 8, 27 Although the secreted Ab was effectively inhibited in the presence of a g-secretase inhibitor, the inhibition was not effective with respect to the cellular levels of Ab. We do not know why the cellular levels of Ab were not reduced by the g-secretase inhibitor treatment, but one explanation might be the inability of the inhibitor to enter the human fibroblast cells.
The neurological manifestations in this family are also prevalent in other EOAD 28 cases and is considered as secondary to the neurodegenerative process. In the described family, all patients had some neurological dysfunctions, such as falls, myoclonus, or epileptic seizures. Experimental data indicate that high levels of Ab in hAPP transgenic mouse brains might cause epileptic activity and contribute to cognitive decline. 28, 29 We showed that the PSEN1 mutation carriers had severe Ab pathology, using both immunohistochemical staining and mass spectrometry analysis, which might have triggered the myoclonus and epileptic manifestations.
As the Ab43 peptide is more hydrophobic than Ab42, and as longer forms polymerize faster and at lower concentrations than the more abundant shorter variants, it is plausible that the Ab43 isoform also forms toxic oligomers to a greater extent than Ab40 and Ab42 in vivo. However, in postmortem studies, such as this one, initiating events of the disease cannot be observed. As Ab oligomers seem to be of particular importance as neurotoxins, further studies on the presence of Ab43 oligomers are warranted. Furthermore, in vivo and in vitro studies focusing on Ab43 are encouraged, in particular with respect to the design of Ab vaccination trials.
In summary, we identified an I143T PSEN1 mutation in a Swedish family, which is the sixth AD mutation found in Sweden that causes an aggressive form of EOAD. We also found a longer Ab species, Ab43, which was present in each examined brain area, except for the cerebellum, which was, on the other hand, more extensively affected by Ab40. Although the absolute levels of Ab43 were low, it was clearly more frequent than Ab40, thus indicating that Ab43 has an important role in the disease process of AD.
